Joris Vandeputte

Profile: Dr. Veterinary Medicine, virologist, active in global networking in human and animal health, vaccines and diagnostics, global disease control, one health_,_ public affairs with EU, WHO, Asian and African authorities and experienced in vaccine translational development.

CV in brief:

·      Research Virology at Ghent University, faculty of Veterinary Medicine: discovery of H1N1 influenza in swine and its zoonotic role, in collaboration with WHO reference Centre in Munich. Vaccination in swine and bovine.

·      Global Head of business units vaccines for swine and ruminants, director scientific support and director international regulatory affairs at Rhône-Mérieux, Merial, now Boehringer Ingelheim.

·      Part of the initial GAVI/Vaccine Fund team, creating sustainable collaboration between GAVI/The Vaccine Fund and the EU.

·      VP resource mobilization for tuberculosis vaccines and support to tuberculosis vaccine development at TBVI.

·      GALVMED: supporting the animal vaccine networks in Africa

·      European research programs: work package leader, regulatory, of EU/IMI projects ZAPI (platform technologies for human and animal vaccines, pandemic preparedness), VAC2VAC ( 3R’s in vitro batch control) and MANCO (development of monoclonal antibodies against SARS-CoV-2); participation in EU/IMI projects DRIVE (flu vaccine effectiveness) and INNO4VAC (human infection models), Co-Lead regulatory in the CEPI/HERA project, the Global consortium on human challenge studies in hunt for transmission-blocking coronavirus vaccines

·      Others:  overview of animal challenge models for COVID-19 vaccines, correlates of protection for COVID-19 vaccines, participating in strategies on pandemic preparedness, high pathogenic influenza and African Swine Fever control.

·      Global plan for rabies control by 2030:  support in establishing the global plan ZERO Rabies by 2030 a joined initiative by WHO, WOAH, FAO and GARC.

·       President of IABS (international Alliance for Biological Standardization) 2016-2022, member of the board of IABS, advisor to vaccine companies and various disease control initiatives.

·      Member of the advisory board of the World Vaccine Congress.